340B Drug Discounts: An Increasingly Dysfunctional Program

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This report reviews the federal 340B drug discount program, showing that, over the past decade, the revenue for hospitals generated by the program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide. The study notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

Download: 340B Drug Discounts: An Increasingly Dysfunctional Program